A Phase 2/3 interventional study of Rivaroxaban 2.5 MG [Xarelto] and Placebo in Type II Myocardial Infarction, sponsored by University of Alberta. Completed at 1 site in Canada. Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2023-03-27.
Sponsored by University of Alberta · Phase 2/3, Interventional, and Treatment
This trial is the pilot phase of a randomized controlled trial to test the feasibility of recruiting patients with a type 2 myocardial infarction and randomizing them to low-dose rivaroxaban to reduce the risk of major cardiovascular events.
This trial is an investigator-initiated prospective, single-center, placebo-controlled, double blinded, pilot randomized controlled trial of low-dose rivaroxaban (2.5mg oral twice daily) for 90-days following a type 2 myocardial infarction. The primary feasibility outcome is time to recruitment of 100 participants, stratified by sex.
2,744 studies on the registry are indexed under Myocardial Infarction; 418 are open to participants now.
This study's enrollment of 8 is below the median of 148 across 1,595 interventional studies indexed under Myocardial Infarction.
Browse Myocardial Infarction studies →University of Alberta is the lead sponsor of 800 studies on the registry; 168 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Rivaroxaban 2.5mg oral twice daily for 90-days
Drug: Rivaroxaban 2.5 MG [Xarelto]
Oral placebo tablet twice daily for 90-days
Drug: Placebo
Rivaroxaban 2.5mg twice daily for 90-days
Placebo tablet twice daily for 90-days
Feasibility outcome
Time to recruitment of 100 participants, stratified by sex.
Time frame: Through study completion, estimated at 1-year
Number of participants who experience a composite of death, stroke or myocardial infarction
Composite of death, stroke or myocardial infarction
Time frame: 90-days
Number of participants who experience major bleeding
Major bleeding as per the International Society on Thrombosis and Haemostasis (ISTH) Fatal bleeding, symptomatic bleeding requiring presentation to an acute care facility or bleeding resulting in transfusion.
Time frame: 90-days
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Alberta